Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase Ib dose-finding trial of lapatinib plus pegylated liposomal doxorubicin in advanced HER2-positive breast cancer.
Rocca A, Cecconetto L, Passardi A, Melegari E, Andreis D, Monti M, Maltoni R, Sarti S, Pietri E, Schirone A, Fabbri F, Donati C, Nanni O, Fedeli A, Faedi M, Amadori D. Rocca A, et al. Among authors: melegari e. Cancer Chemother Pharmacol. 2017 May;79(5):863-871. doi: 10.1007/s00280-017-3279-8. Epub 2017 Mar 24. Cancer Chemother Pharmacol. 2017. PMID: 28341957 Free PMC article. Clinical Trial.
Trastuzumab-induced cardiotoxicity in early breast cancer patients: a retrospective study of possible risk and protective factors.
Farolfi A, Melegari E, Aquilina M, Scarpi E, Ibrahim T, Maltoni R, Sarti S, Cecconetto L, Pietri E, Ferrario C, Fedeli A, Faedi M, Nanni O, Frassineti GL, Amadori D, Rocca A. Farolfi A, et al. Among authors: melegari e. Heart. 2013 May;99(9):634-9. doi: 10.1136/heartjnl-2012-303151. Epub 2013 Jan 24. Heart. 2013. PMID: 23349345
Efficacy of endocrine therapy in relation to progesterone receptor and Ki67 expression in advanced breast cancer.
Rocca A, Farolfi A, Maltoni R, Carretta E, Melegari E, Ferrario C, Cecconetto L, Sarti S, Schirone A, Fedeli A, Andreis D, Pietri E, Ibrahim T, Montalto E, Amadori D. Rocca A, et al. Among authors: melegari e. Breast Cancer Res Treat. 2015 Jul;152(1):57-65. doi: 10.1007/s10549-015-3423-2. Epub 2015 May 27. Breast Cancer Res Treat. 2015. PMID: 26012644
Androgen receptor signaling pathways as a target for breast cancer treatment.
Pietri E, Conteduca V, Andreis D, Massa I, Melegari E, Sarti S, Cecconetto L, Schirone A, Bravaccini S, Serra P, Fedeli A, Maltoni R, Amadori D, De Giorgi U, Rocca A. Pietri E, et al. Among authors: melegari e. Endocr Relat Cancer. 2016 Oct;23(10):R485-98. doi: 10.1530/ERC-16-0190. Epub 2016 Aug 15. Endocr Relat Cancer. 2016. PMID: 27528625 Review.
Precision medicine: PI3K targeting in advanced breast cancer.
Rocca A, Melegari E, Palleschi M. Rocca A, et al. Among authors: melegari e. Breast Cancer Res Treat. 2019 Nov;178(2):479. doi: 10.1007/s10549-019-05409-3. Epub 2019 Aug 19. Breast Cancer Res Treat. 2019. PMID: 31428907 No abstract available.
Ribociclib and Endocrine Therapy in Breast Cancer.
Rocca A, Melegari E, Palleschi M. Rocca A, et al. Among authors: melegari e. N Engl J Med. 2019 Oct 17;381(16):1592. doi: 10.1056/NEJMc1911188. N Engl J Med. 2019. PMID: 31618549 No abstract available.
12 results